Probiotic Potential of Lacticaseibacillus casei Isolated From Traditional Dairy Products and Its Hepatoprotective Effects in STZ-Induced Diabetic Rats.

2025-12
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 133(12)

PubMed: 41334666
DOI: 10.1111/apm.70112

Study Design

Type: Clinical Trial
Population: streptozotocin-induced diabetic rats
Methods: 15 lactic acid bacteria were isolated from traditional dairy products in Northwestern Iran and assessed for probiotic properties; strain ad1 was administered to streptozotocin-induced diabetic rats for 4 weeks

Animal Study

Type 2 diabetes mellitus is linked to liver dysfunction and gut dysbiosis, and probiotics, especially Lactobacillus strains, are considered potential biotherapeutics for improving metabolic health. In this study, 15 lactic acid bacteria were isolated from traditional dairy products in Northwestern Iran and assessed for probiotic properties, including acid and bile tolerance, aggregation, hydrophobicity, antibacterial activity, and safety. Strain ad1 exhibited high acid (71.13% ± 0.62% at pH 2.5, 3 h) and bile tolerance (74.31% ± 0.65% at 0.3% oxgall, 4 h), strong autoaggregation (69.61%), and broad antibacterial activity, notably against Staphylococcus aureus (21.4 mm inhibition zone). Additionally, it was non-hemolytic and sensitive to all eight tested antibiotics. To evaluate its antidiabetic potential, ad1 was administered to streptozotocin-induced diabetic rats for 4 weeks. Results showed significant reductions in ALT (60.6 ± 1.3 to 45.5 ± 0.8 U/L), AST (93.5 ± 1.0 to 60.1 ± 1.2 U/L), ALP (264.1 ± 34.2 to 191.3 ± 28.2 U/L), and blood glucose (311.9 ± 37.2 to 153.1 ± 36.9 mg/dL, p < 0.05). Histopathological analysis confirmed reduced hepatic damage and steatosis. In conclusion, Lacticaseibacillus casei strain ad1 shows strong probiotic potential, along with hepatoprotective and antihyperglycemic effects, making it a promising candidate for T2DM management.

Research Insights

Supplement	Dose	Health Outcome	Effect Type	Effect Size	Source
Lacticaseibacillus casei	—	Reduced Blood Glucose Levels	Beneficial	Large	View source and blood glucose (311.9 ± 37.2 to 153.1 ± 36.9 mg/dL, p < 0.05).
Lacticaseibacillus casei	—	Reduced Liver Enzyme Levels	Beneficial	Moderate	View source Results showed significant reductions in ALT (60.6 ± 1.3 to 45.5 ± 0.8 U/L), AST (93.5 ± 1.0 to 60.1 ± 1.2 U/L), ALP (264.1 ± 34.2 to 191.3 ± 28.2 U/L)